Published Ahead of Print on July 25, 2016 as 10.1200/JCO.2016.67.6601
The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2016.67.6601
J C O
OURNAL OF LINICAL NCOLOGY O R I G I N A L R E P O R T
Phase III Randomized Trial of Ipilimumab Plus Etoposide
and Platinum Versus Placebo Plus Etoposide and Platinum in
Extensive-Stage Small-Cell Lung Cancer
Martin Reck,Alexander Luft,AleksandraSzczesna, LiborHavel, Sang-WeKim, Wallace Akerley,
Maria CatherinePietanza, Yi-long Wu, Christoph Zielinski, Michael Thomas,Enriqueta Felip,KathrynGold,
Leora Horn, Joachim Aerts,Kazuhiko Nakagawa,Paul Lorigan, AnnePieters, TeresaKongSanchez,
Justin Fairchild,andDavidSpigel
Authoraffiliationsappearattheendofthis
A B S T R A C T
article.
Publishedonlineaheadofprintat Purpose
www.jco.orgonJuly25,2016. Patientswithextensive-stagediseasesmall-celllungcancer(SCLC)havepoorsurvivaloutcomes
SupportedbyBristol-MyersSquibb,which despitefirst-linechemotherapywithetoposideandplatinum.Thisrandomized,double-blindphaseIII
alsofundedprofessionalmedicalwriting study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in
andeditorialassistance.Bristol-Myers
patientswith newlydiagnosedextensive-stage diseaseSCLC.
Squibbworkedjointlywithinvestigators
tocollectandanalyzethestudyresults. Patients and Methods
Authors’disclosuresofpotentialconflicts Patientswererandomlyassignedataratioofonetoonetoreceivechemotherapywithetoposide
ofinterestarefoundinthearticleonlineat andplatinum(cisplatinorcarboplatin)plusipilimumab10mg/kgorplaceboevery3weeksforatotal
www.jco.org.Authorcontributionsare offourdoseseachinaphasedinductionschedule(chemotherapyincyclesonetofour;ipilimumab
foundattheendofthisarticle.
orplacebobeginningincyclethreeuptocyclesix),followedbyipilimumaborplacebomaintenance
Clinicaltrialinformation:NCT01450761. every12weeks.Primaryendpointwasoverallsurvival(OS)amongpatientsreceivingatleastone
Correspondingauthor:MartinReck,MD, dose ofblindedstudytherapy.
PhD,DepartmentofThoracicOncology,
LungenClinicGrosshansdorf, Results
Grosshansdorf,Germany;e-mail: Of 1,132 patients randomly assigned, 954 received at least one dose of study therapy (chemo-
dr.martin.reck@web.de. therapy plus ipilimumab, n = 478; chemotherapy plus placebo, n = 476). Median OS was
©2016byAmericanSocietyofClinical 11.0monthsforchemotherapyplusipilimumabversus10.9monthsforchemotherapyplusplacebo
Oncology (hazard ratio, 0.94; 95% CI, 0.81 to 1.09; P = .3775). Median progression-free survival was
0732-183X/16/3499-1/$20.00 4.6monthsforchemotherapyplusipilimumabversus4.4monthsforchemotherapyplusplacebo
(hazardratio,0.85;95%CI,0.75to0.97).Ratesandseverityoftreatment-relatedadverseevents
DOI:10.1200/JCO.2016.67.6601
weresimilarbetweenarms,exceptfordiarrhea,rash,andcolitis,whichweremorefrequentwith
chemotherapy plus ipilimumab. Rate of treatment-related discontinuation was higher with che-
motherapy plus ipilimumab (18% v 2% with chemotherapy plus placebo). Five treatment-related
deaths occurredwith chemotherapyplusipilimumab and twowith chemotherapy plusplacebo.
Conclusion
AdditionofipilimumabtochemotherapydidnotprolongOSversuschemotherapyaloneinpatients
withnewlydiagnosedextensive-stagediseaseSCLC.Noneworunexpectedadverseeventswere
observedwithchemotherapyplusipilimumab.Severalongoingstudiesareevaluatingipilimumabin
combinationwith programmed death-1inhibitors in SCLC.
J Clin Oncol 34. © 2016 by American Society of Clinical Oncology
intheUnitedStatesandEurope4-7andirinotecan
INTRODUCTION
plus a platinum agent in Japan.8 Despite high
initial response rates, nearly all patients with
Small-cell lung cancer (SCLC), which accounts
for 10% to 15% of lung cancer cases,1 is an ex- ED-SCLCexperiencediseaserecurrenceorrapid
progression after first-line chemotherapy. The
tremely aggressive tumor type; 70% of pa-
tients present with extensive-stage disease (ED- medianprogression-freesurvival[PFS]isapproxi-
SCLC).2,3Thecurrentfirst-linestandardofcareis mately 2 to 3 months,9 and long-term sur-
platinum-basedchemotherapy(fourtosixcycles vivalremainspoor(2-yearoverallsurvival[OS]
of etoposide plus eithercisplatin orcarboplatin) is , 5%).3,10 Multiple trials evaluating other
©2016byAmericanSocietyofClinicalOncology 1
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
Copyright 2016 by American Society of Clinical Oncology
Recketal
agentsortheadditionofathirddrughavefailedtoshowasignificant chemotherapy;during cycles fiveand sixof induction, patients received
improvement in median OS over etoposide and platinum.3,10,11 only ipilimumab or placebo (Data Supplement). Patients who achieved
Thus, there is a significantneed foreffective therapy. a complete or partial response per modified WHO criteria24 during in-
ductioncouldundergoprophylacticcranialirradiation(PCI;investigator’s
Several lines of evidence provide a rationale for the use of
choice) before the start of the maintenance phase. The maintenance
immunotherapy in SCLC. The high frequency of somatic muta-
phasebegan9to12weeksafterthelastinductioncycle(dependingonthe
tions in SCLC,3,12 along with the presence of autoimmune para- timingofandrecoveryfromPCI,ifadministered).Ipilimumab10mg/kg
neoplasticsyndromes,13,14suggeststhatSCLCisanimmunogenic or placebo was administered every 12 weeks until progression, un-
tumor type. Preliminary studies have shown activity of immune acceptable toxicity, or death, for a maximum of 3 years from the first
checkpoint inhibitors in SCLC.15-17 ipilimumab or placebo dose. The rationale for this dose schedule of
ipilimumabwasbasedonpriorphaseII/IIImelanomaandphaseIIlung
Ipilimumab, a fully human immunoglobulin G1 monoclonal
cancertrials.17,19,23,25-27
antibodythatabrogatesbindingofthecheckpointproteincytotoxic
Random assignment was stratified by ECOG PS (0 v 1), lactate
T-celllymphocyteantigen-4(CTLA-4)withitsligands,significantly
dehydrogenaselevel(#upperlimitofnormalv.upperlimitofnormal),
improvedOSinpatientswithadvancedmelanomaintwophaseIII choiceofplatinumagentduringinduction(cisplatinvcarboplatin),and
trials.18-20Ipilimumabhasalsobeenevaluatedincombinationwith region(NorthAmericaorWesternEuropevother).Criteriafortreatment
chemotherapyinpreclinicalandclinicalstudiesofdifferenttumor delay and discontinuation because of treatment-related adverse events
types.17,19,21-23 In a phase II trial, ipilimumab administered in (AEs) are detailed in the Data Supplement. No dose reductions were
a phased regimen with carboplatin and paclitaxel significantly permittedforipilimumaborplacebo.Resultsareprovidedforpatientswho
weretreatedwithatleastonedoseofblindedstudydrug.
improvedimmune-relatedPFSovercarboplatinandpaclitaxelalone
andshowedanumericthoughnotstatisticallysignificantincreasein
Treatment Assessments
median OSovercarboplatinandpaclitaxel(12.9 v9.9 months) in
Tumorassessment(includingboneorbrainimaging)performedat
patients with previously untreated ED-SCLC.17 The phased ipili- screeningwasusedasbaselineforefficacyassessments.Tumor response
mumab regimen also significantly improved immune-related PFS wasinvestigatorassessedpermodifiedWHOcriteriaatweeks7,13,19,and
and PFS over carboplatin and paclitaxel alone in patients with 25andthenevery12weeksthereafteruntilprogressionorendoftreat-
previouslyuntreated non-SCLC(NSCLC).23ThephaseIIresults17 ment.SafetywasassessedbyevaluatingtheincidenceofAEsandlaboratory
and preclinical data22 led to the initiation of this multicenter, parameters and graded using National Cancer Institute Common Ter-
minologyCriteriaforAdverseEvents(version3.0).AEsofinterestwere
randomized,double-blindphaseIIItrialevaluatingipilimumabor
definedasthosewithpotentialimmunologicetiologiesandgroupedinto
placebo in combination with etoposide and platinum therapy in
predefinedcategories:enterocolitis,dermatitis,hepatitis,endocrinopathies,
patientswithnewlydiagnosedED-SCLC(CA184-156study[clinical
andneuropathies.AEsofinterestconsidereddrugrelatedbytheinvestigator
trial information:NCT01450761]). werereferredtoasimmune-relatedAEs.
End Points
PATIENTSANDMETHODS
TheprimaryendpointwasOSamongpatientswhoreceivedatleast
onedoseofstudytherapy.Patientswereobservedcontinuouslyforsur-
Patients vivalwhilereceivingtreatmentandthenevery3monthsaftertreatment
PatientswithdocumentedED-SCLCwereeligible.Inclusioncriteria discontinuation.
included age 18 years or older, Eastern Cooperative Oncology Group ThetrialwasoriginallydesignedwithaprimaryendpointofOSinall
performancestatus(ECOGPS)of0or1,andnopriorsystemictherapyfor randomlyassignedpatients.Duringthestudy,itwasdeterminedthattheeffect
ED-SCLC. Exclusion criteria included brain metastasis requiring treat- ofipilimumabonOScouldnotbeaccuratelymeasuredinthispopulationofall
ment, uncontrolled pleural effusion, autoimmune disease, systemic im- thoserandomlyassigned.Toavoidattenuationofthepotentialtreatmenteffect,
munosuppression,andanycancerimmunotherapy. theendpointsweremodifiedbyaprotocolamendment.
Thestudyprotocolwasapprovedbytheinstitutionalreviewboardor SecondaryendpointsincludedOSinallrandomlyassignedpatients
ethics committee at each participating center as appropriate and was andPFSpermodifiedWHOcriteriaamongpatientswhoreceivedatleast
conducted in accordance with the Declaration of Helsinki and In- one dose of study therapy. Exploratoryend points included bestoverall
ternational Conference on Harmonisation Guidelines for Good Clinical responserate(ORR),durationofresponse,survivalrate,andsafety.
Practice. All patients provided written informed consent before enroll-
ment. An independent data and safety monitoring committee provided
oversightofsafetyandefficacy. StatisticalAnalyses
EstimationofsamplesizewasbasedontheresultsofaphaseIIstudy
in ED-SCLC and NSCLC.17,23 Approximately 1,100 patients were to be
Study Design and Treatment Plan randomlyassignedataratioofonetoone;assumingadropoutrateof15%
Thestudyconsistedofinductionfollowedbyamaintenancephase duringthefirsttwocyclesofchemotherapy,itwasestimated935patients
(DataSupplement).Patientswererandomlyassignedataratioofoneto wouldreceivestudydrug.Theprimaryanalysiswasnotconducteduntil
onetoreceiveipilimumab10mg/kgintravenously(IV)orplacebousingan atotalof618eventshadoccurredin935randomlyassignedpatientswho
interactive voice response system with a stratified, permuted, block- receivedstudytherapy,whichwasestimatedtoensure90%powertodetect
randomization method. Research staff was blinded to treatment assign- astatisticallysignificantdifferenceinOS,withatypeIerrorrateof5%
ment. Ipilimumab or placebo was administered in a phased dosing basedonatwo-sided log-ranktest.Forthispowercomputation,anex-
regimen.Duringcyclesonetofourofinduction(3-weekcycles),patients ponential distribution and a true hazard ratio (HR) of 0.77 in the
inbotharmsreceivedetoposide100mg/m2IVondays1,2,and3ofeach post-chemotherapy alone period was assumed. The expected smallest
cycleandinvestigator’schoiceofplatinum agent onday1of eachcycle statisticallysignificanttreatmenteffectcorrespondedtoanHRof0.85.
(cisplatin75mg/m2IVorcarboplatinareaundertheconcentration-time For OS and PFS, treatment arms were compared using an un-
curve 5 IV). During cycles three and four of induction, patients re- stratified,two-sidedlog-ranktest.HRsandcorresponding95%CIswere
ceived ipilimumab 10 mg/kg or placebo (3-week cycles) in addition to estimatedusinganunstratifiedCoxmodelwithtreatmentarmastheonly
2 ©2016byAmericanSocietyofClinicalOncology JOURNALOFCLINICALONCOLOGY
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
IpilimumabPlusChemotherapyVersusChemotherapyinFirst-LineED-SCLC
covariate.SurvivalcurvesandrateswereestimatedusingtheKaplan-Meier arm). A total of 1,123 patients received treatment (one or more
method.BestORRpermodifiedWHOcriteriawascalculatedinevaluable
cycleofplatinumandetoposide);themostcommonreasonfornot
patients,andcorresponding95%exactCIwascalculatedusingtheClopper- receiving treatment was that the patient no longer met eligibility
Pearsonmethod.Statisticalconsiderationsinallrandomlyassignedpatients
criteria.Ofthosetreated,15%ofpatients(n=169)discontinued
arepresentedintheDataSupplement.
duringcyclesonetotwo,beforeadministrationofstudydrug,and
85%(n=954)receivedatleastonedoseofblindedstudytherapy
RESULTS (chemotherapy plus ipilimumab, [n = 478]; chemotherapy plus
placebo,[n=476];Fig1;DataSupplement).Thisreportfocuses
Patients and Treatment on efficacy and safety analyses performed in randomly assigned
From January 2012 to September 2014, 1,414 patients were patients who received at least one dose of blinded study drug.
enrolled at 224 study sites in 34 countries, with 1,132 patients Analyses in the population of all those randomly assigned are
randomly assigned to receive etoposide and platinum plus ipili- presented in the Data Supplement.
mumab (chemotherapy plus ipilimumab) or etoposide and plat- Median age of the treated patient population was 62 years;
inum plus placebo (chemotherapy plus placebo; n = 566 in each mostpatientsweremale(67%)andwhite(76%),withanECOG
Assessed for eligibility
Enrollment
(N = 1,414)
Excluded (n = 282)
Not eligible for randomization (n = 282)
Did not meet inclusion criteria (n = 234)
Declined to participate (n = 21)
Other reasons (n = 27)
Randomly assigned
(n = 1,132) Fig1. CONSORTdiagram.Dispositionof
patientswithextensive-stagesmall-celllung
cancerinstudyCA184-156asofSeptember
2015.Patientswererandomlyassignedto
chemotherapy plus ipilimumab (etoposide
Allocated to chemotherapy plus Allocation Allocated to chemotherapy plus plusinvestigator’schoiceofcisplatinorcar-
ipilimumab (n = 566) and placebo (n = 566) boplatinincyclesonetofourandipilimumab
Treated (n = 562) Treatment Treated (n = 561) incyclesthreetosix)orchemotherapyplus
Not treated (n = 4) Not treated (n = 5) placebo(etoposideplusinvestigator’schoice
Received ipilimumab (n = 478) Received placebo (n = 476)
ofcisplatinorcarboplatinincyclesonetofour
Did not receive ipilimumab (n = 84) Did not receive placebo (n = 85)
andplaceboincyclesthreetosix).Patients
Disease progression (n = 33) Disease progression (n = 32)
AE unrelated to study drug (n = 21) AE unrelated to study drug (n = 19) whoachievedcompleteorpartialresponse
Study drug toxicity (n = 6) Study drug toxicity (n = 10)
permodifiedWHOcriteria24duringinduction
Withdrew consent (n = 8) Withdrew consent (n = 8) couldundergoprophylacticcranialirradi-
No longer met study criteria (n = 3) No longer met study criteria (n = 7) ation(PCI),investigator’schoice,before
Requested to discontinue Requested to discontinue startofmaintenancephase.Maintenance
treatment (n = 6) treatment (n = 4) phasebegan9to12weeksafterlastin-
Died (n = 3) Died (n = 3) ductioncycle(dependingontimingofand
Lost to follow-up (n = 2) Other (n = 2) recovery from PCI, if administered), in
Other (n = 2) which ipilimumab 10 mg/kg or placebo
wasadministeredintravenouslyevery12
weeks until progression, unacceptable
Completed induction phase (n = 260) Completed induction phase (n = 300) toxicity,ordeath,foramaximumperiod
Entered maintenance phase (n = 64) Follow-up Entered maintenance phase (n = 82) of3yearsfromfirstipilimumaborplacebo
Still receiving treatment (n = 14) Still receiving treatment (n = 10)
dose.Reasonsforpatientsdiscontinuing
No longer receiving treatment (n = 464) No longer receiving treatment (n = 466)
duringinductionphaseareindicated.AE,
Progressive disease (n = 314) Progressive disease (n = 409)
adverseevent.
Study drug toxicity (n = 85) Study drug toxicity (n = 9)
AE unrelated to study drug (n = 25) AE unrelated to study drug (n = 19)
Withdrew from treatment (n = 25) Withdrew from treatment (n = 13)
Died (n = 5) Died (n = 6)
Other (n = 5) Other (n = 4)
Lost to follow-up (n = 2) Lost to follow-up (n = 1)
Maximum clinical benefit (n = 1) Maximum clinical benefit (n = 2)
No longer met study criteria (n = 1) No longer met study criteria (n = 2)
Noncompliance (n = 1) Not reported (n = 1)
Efficacy (n = 566) Analysis Efficacy (n = 566)
Safety (n = 562) Safety (n = 561)
www.jco.org ©2016byAmericanSocietyofClinicalOncology 3
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
Recketal
PS of 1 (70%). Demographic and baseline characteristics were inthemaintenancephase(chemotherapyplusipilimumab,[n=14];
balanced between the two arms (Table 1). chemotherapyplusplacebo,[n=10]);themostcommonreason
Themediannumberofdosesofblindedstudydrugreceived for discontinuation was disease progression (Fig 1; Data Sup-
wasfour(ipilimumab,rangeoneto14;placebo,rangeoneto12); plement). PCIwasadministered to11% and 14% of patientsin
59%receivedatleastfourdosesofipilimumab,and69%received the chemotherapy plus ipilimumab and chemotherapy plus
atleastfourdosesofplacebo.Thenumberofpatientswhoreceived placebo arms, respectively. Subsequent chemotherapy was ad-
carboplatin or cisplatin as backbone chemotherapy was similar ministeredto48%and52%ofpatientsinthechemotherapyplus
betweentreatmentarms(DataSupplement).Acrossarms,15%of ipilimumab and chemotherapy plus placebo arms, respectively
patients (n = 146) received at least one dose of maintenance (Data Supplement).
therapy(ipilimumab,13%[n=64];placebo,17%[n=82];Fig1).
Atdatabaselock(June10,2015),3%ofpatients(n=24)continued
Efficacy
At database lock, 74% of patients (n = 707) who received
blindedstudytherapyhaddied.Medianfollow-upforOSwas10.5
Table1. BaselineCharacteristics,StratificationFactors,andPriorTherapy and 10.2 months in the chemotherapy plus ipilimumab and
No.(%) chemotherapy plus placebo arms, respectively.
Chemotherapy plus ipilimumab treatment did not result in
ChemotherapyPlus ChemotherapyPlus
Ipilimumab Placebo a statistically significant improvement in OS compared with
Characteristic (n=478) (n=476) chemotherapy plusplacebo among patients who receivedat least
Age,years onedoseofblindedstudytherapy(HR,0.94;95%CI,0.81to1.09;
Median 62 63 unstratified log-rank P = .3775). Median OS was 11.0 months
Range 39to85 36to81
(95% CI, 10.45 to 11.33) in patients treated with chemotherapy
Agecategorization,years
,65 299(63) 277(58) plusipilimumabversus10.9months(95%CI,10.02to11.50)in
$65 179(37) 199(42) thosetreatedwithchemotherapyplusplacebo,with1-yearOSrates
Sex
of40%inbotharms(Fig2A).Atthetimeofanalysis,350patients
Male 317(66) 326(68)
Female 161(34) 150(32) (73%) in the chemotherapy plus ipilimumab arm had died,
Race comparedwith357(75%)inthechemotherapyplusplaceboarm.
White 365(76) 359(75) Across most prespecified patient subgroups, HRs for OS did not
Asian 108(23) 107(22)
seem to favor one treatment arm (Fig 2B). Results for OS in the
Black/AfricanAmerican 3(1) 5(1)
Other 2(,1) 5(1) populationofallrandomlyassignedpatientswereconsistentwith
Region the primary analysis results (Data Supplement).
NorthAmericaor 186(39) 197(41) MedianPFSwas4.6months(95%CI,4.50to4.99)inpatients
WesternEurope
Restofworld* 292(61) 279(59) treated with chemotherapy plus ipilimumab versus 4.4 months
ECOGPS (95% CI, 4.37 to 4.63) in those treated with chemotherapy plus
0 137(29) 147(31) placebo;HRwas0.85(95%CI,0.75to0.97;unstratifiedlog-rank
1 340(71) 328(69)
P=.0161)betweenarms(Fig3).Atthetimeofanalysis,443(93%)
2 1(,1) 1(,1)
CNSmetastasisatbaseline 55(12) 45(10) and457patients(96%)inthechemotherapyplusipilimumaband
Smokingstatus chemotherapy plus placebo arms, respectively, had experienced
Heavysmoker† 268(56) 271(57) diseaseprogression.Furthermore,becausetheprimaryendpoint
Lightornonsmoker‡ 172(36) 167(35)
ofthestudywasnotmet,thePvaluesofallsecondaryendpoints,
Unknown 9(2) 11(2)
Missing 29(6) 27(6) including PFS, are provided for descriptive purposes only and
LDHlevel should not be considered statistically significant.
.ULN 231(48) 228(48)
BestORRsweresimilarinthetwoarms.Inthechemotherapy
#ULN 242(51) 246(52)
Notreported 2(,1) 2(,1) plusipilimumabandchemotherapyplusplaceboarms,respectively,
Choiceofplatinumduring 62% (in each arm) experienced partial responses, 26% and 27%
induction experiencedstabledisease,and6%and9%experiencedprogressive
Cisplatin 164(34) 159(33)
disease. One patient treated with chemotherapy plus ipilimumab
Carboplatin 314(66) 317(67)
Patientswithpriorsurgery 65(14) 72(15) experienced a complete response; none were observed in patients
Patientswithprior 14(3) 8(2) treated with chemotherapy plus placebo. Median duration of re-
radiotherapy
sponsewas4.01(95%CI,3.32to4.17)and3.45months(95%CI,
Timefrominitialdiagnosis
tofirstdose,months 3.25 to 4.07) with chemotherapy plus ipilimumab and chemo-
Median 0.6 0.5 therapy plusplacebo, respectively (Table2).
Range 0to109.2 0to1,081.6
Abbreviations:ECOGPS,EasternCooperativeOncologyGroupperformance Safety
status;LDH,lactatedehydrogenase;ULN,upperlimitofnormal.
*Includes countries in Africa, Asia, Australia, Eastern Europe, and South Rate of treatment-related AEs occurring on or after blinded
America. study drug dosing was 82% (48% for grade 3 to 4 events) with
†Definedas.20pack-yearsandcurrentlysmokingorstopped,1yearago.
‡Allpatientswhodidnotmeetcriteriaforheavysmoker. chemotherapy plus ipilimumab and 76% (44% for grade 3 to 4
events) with chemotherapy plus placebo (Table 3). The most
4 ©2016byAmericanSocietyofClinicalOncology JOURNALOFCLINICALONCOLOGY
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
A
Chemotherapy plus ipilimumab Chemotherapy plus placebo
No. events/No. of patients 350/478 357/476
*Median OS (95% CI), mo 11.0 (10.5 to 11.3) 10.9 (10.0 to 11.5)
100 †HR (95% CI) 0.94 (0.81 to 1.09)
‡Log-rank P .3775
80
60 1-year OS rate = 40%
40
20
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
Time Since Random Assignment (months)
No. of patients at risk
Chemotherapy plus ipilimumab 478 477 450 394 318 259 172 112 78 41 28 22 15 10 7 2 0
Chemotherapy plus placebo 476 476 454 398 320 245 158 104 64 38 27 17 5 3 0 0 0
B Ipilimumab Placebo
No. of events No. of events HR
(No. of patients) (No. of patients) (95% Cl)
Age < 65 years 224 (299) 211 (277) 1.08 (0.90 to 1.31)
Age ≥ 65 to < 75 years 100 (147) 118 (159) 1.14 (0.87 to 1.49)
Age ≥ 75 years 26 (32) 28 (40) 0.70 (0.40 to 1.20)
Female and age < 50 years 15 (22) 10 (12) 1.26 (0.56 to 2.85)
Female and age ≥ 50 years 102 (139) 101 (138) 1.04 (0.79 to 1.39)
White 280 (365) 284 (359) 1.05 (0.89 to 1.24)
Black 2 (3) 3 (5) 0.60 (0.10 to 3.68)
Asian 66 (108) 65 (107) 1.16 (0.82 to 1.64)
Other race 2 (2) 5 (5) 3.32 (0.38 to 28.94)
Male 233 (317) 246 (326) 1.07 (0.89 to 1.28)
Female 117 (161) 111 (150) 1.06 (0.81 to 1.37)
Baseline ECOG PS of 0 94 (137) 116 (147) 1.28 (0.98 to 1.69)
Baseline ECOG PS of 1 255 (340) 240 (328) 0.99 (0.83 to 1.18)
North America or Western Europe 149 (183) 156 (194) 1.00 (0.80 to 1.25)
Other region 201 (295) 201 (282) 1.11 (0.91 to 1.35)
Heavy smoker 194 (268) 204 (271) 1.09 (0.89 to 1.32)
Ex-, light, or nonsmoker 130 (172) 126 (167) 1.02 (0.80 to 1.30)
Carboplatin 238 (314) 250 (317) 1.14 (0.96 to 1.37)
Cisplatin 112 (164) 107 (159) 0.93 (0.71 to 1.21)
Baseline LDH elevated 186 (231) 187 (228) 1.10 (0.90 to 1.35)
Baseline LDH within ULN 163 (245) 169 (246) 1.08 (0.87 to 1.34)
CNS metastasis 41 (55) 41 (45) 1.58 (1.02 to 2.44)
No CNS metastasis 309 (423) 316 (431) 1.03 (0.88 to 1.20)
0 5
Favors treatment Favors placebo
)%(
lavivruS
llarevO
IpilimumabPlusChemotherapyVersusChemotherapyinFirst-LineED-SCLC
1-year OS rate = 40%
Fig2. (A)Overallsurvival(OS)and(B)treatmenteffectonOSinpredefinedsubsets.(A)Kaplan-MeierplotofOS(chemotherapyplusipilimumab,[n=478];che-
motherapyplusplacebo,[n=476]).OSwasdefinedastimefromdateofrandomassignmentuntildateofdeath.Asindicatedbysymbols,patientswhohadnotdiedor
werelosttofollow-upwerecensoredonthelastdatetheywereknowntobealive.HorizontallinesindicateratesofOSat1year.(B)ForestplotoftreatmenteffectonOSin
predefinedsubsetsbasedonunstratifiedCoxproportionalhazardsmodelforpatientsinindicatedsubset.Hazardratios(HRs)andtwo-sided95%CIswerecalculatedasin
panelA.ECOGPS,EasternCooperativeOncologyGroupperformancestatus;LDH,lactatedehydrogenase;ULN,upperlimitofnormal.(*)Mediansandassociatedtwo-
sidedCIscalculatedvialog-logtransformation.(†)Hazardofipilimumaboverhazardofplacebowithtwo-sided95%CIisbasedonunstratifiedCoxproportionalhazards
modelwithtreatmentassinglecovariate.(‡)Unstratifiedtwo-sidedlog-ranktest.
www.jco.org ©2016byAmericanSocietyofClinicalOncology 5
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
Chemotherapy plus ipilimumab Chemotherapy plus placebo
No. of events/No. of patients 443/478 457/476
*Median PFS (95% CI), mo 4.6 (4.5 to 5.0) 4.4 (4.4 to 4.6)
100 †HR (95% CI) 0.85 (0.75 to 0.97)
‡Log-rank P .0161
80
60
40
20
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
Time Since Random Assignment (months)
No. of patients at risk
Chemotherapy plus ipilimumab 478 472 382 131 77 48 25 16 13 8 6 5 2 2 1 0
Chemotherapy plus placebo 476 468 362 110 64 30 18 13 5 4 2 1 1 0 0 0
frequentlyreportedgrade3to4treatment-relatedAEsoccurringin5% v,1%),andalopecia(5%v7%).Endocrineimmune-relatedAEs
ofpatientsormoreinthechemotherapy plusipilimumabarmwere occurredin10%ofpatientsinthechemotherapyplusipilimumab
neutropenia(14%),anemia(8%),diarrhea(7%),anddecreased armversus 2% in the chemotherapy plus placebo arm; the most
neutrophilcount(7%).Inthechemotherapyplusplaceboarm,they frequently reported events in 1% or more of patients were hy-
were neutropenia (24%), anemia (11%), and decreased neutrophil pothyroidism (3%), hyperthyroidism (2%), hypophysitis (1%),
count (6%). Frequency of treatment-related serious AEs was nu- andadrenalinsufficiency(1%),asshownintheDataSupplement.
merically higher with chemotherapy plus ipilimumab (any grade, Inthechemotherapy plusipilimumabarm,mediantimesto
27%;grade3to5,22%)versuschemotherapyplusplacebo(anygrade, onsetofgrade2to5immune-relatedAEsrangedfrom4.7weeksin
13%;grade3to5,11%;DataSupplement).Amajorityoftreatment- the skin category to 9.0 weeks in the hepatic category (Data
relatedseriousAEsoccurredinlessthan1%ofpatients;incidencewas Supplement). Immune-related AEs were managed using estab-
similarbetweenarms,withtheexceptionofdiarrhea(anygrade,8%v lishedsafetyguidelines.Atdatabaselock,amajority(76%;184of
1%) and colitis (any grade, 5% v , 1%), which occurred more 243)ofgrade2to4immune-relatedAEscompletelyresolved,with
frequentlywithchemotherapy plusipilimumab(DataSupplement). median times to resolution ranging from 2.0 weeks for hepatic
Treatment-related AEs led to discontinuation in 18% of pa- events to 28.9 weeks for neurologic events (Data Supplement).
tientstreatedwithchemotherapyplusipilimumaband2%ofthose
treatedwithchemotherapy plusplacebo(DataSupplement).The
most frequent treatment-related AEs leading to discontinuation DISCUSSION
were diarrhea (5%) and colitis (4%) with chemotherapy plus
ipilimumab.Inthechemotherapyplusipilimumabarm,therewere To our knowledge, study CA184-156 is the largest phase III
fivetreatment-relateddeaths,tworesultingfromcolitis,twofrom randomizedtrialconductedtodateinapopulationofpatientswith
sepsis,andonefromlivertoxicity.Thetwodeathsresultingfrom ED-SCLC.Theadditionofipilimumabtoetoposideandplatinum
sepsis were assessed by investigators as being related to chemo- didnotresultinastatisticallysignificantimprovementinOSversus
therapy but not ipilimumab. In the chemotherapy plus placebo etoposide and platinum. Although exploratory in nature, che-
arm,thereweretwotreatment-relateddeaths,oneresultingfrom motherapy plus ipilimumab did not demonstrate significant im-
sepsisandonefrombonemarrowsuppression(DataSupplement). provement in other end points, and no subgroups demonstrated
GI and skin-related AEs were the most common immune- greaterbenefitversuschemotherapyalone.Baselinecharacteristics
relatedAEswithchemotherapyplusipilimumab(in34%and29% were well balanced between arms; treatment delivery was com-
ofpatients,respectively).Themostfrequentlyreportedimmune- parable,andthefrequencyandreasonsforpatientsdiscontinuing
relatedAEsin5%ormoreofpatientstreatedwithchemotherapy duringcyclesoneandtwo(beforestartofblindedstudydrug)and
plusipilimumabversuschemotherapyplusplacebowerediarrhea in patients who went on to receive at least one dose of blinded
(25%v10%),rash(19%v3%),pruritus(12%v2%),colitis(6% studydrugwereconsistentwithpriorobservations.17,23Post-study
)%(
lavivruS
eerF-noissergorP
Recketal
Fig3. Kaplan-Meierplotofprogression-freesurvival(PFS).Chemotherapyplusipilimumab,(n=478);chemotherapyplusplacebo,(n=476).PermodifiedWHOcriteria,24
increaseintargetlesionsof$25%frombaseline,progressionofnonindexlesions,orpresenceofnewlesion(measurableornot)isconsideredprogression.PFSper
modifiedWHOcriteriawasdefinedasthetimebetweendateofrandomassignmentanddateofprogressionpermodifiedWHOcriteriaordeath,whicheveroccurredfirst.
Asindicatedbysymbols,patientswhowerealiveanddidnotexperienceprogressionwerecensoredonthedateoflastevaluabletumorassessment.HR,hazardratio.
(*)Mediansandassociatedtwo-sidedCIscalculatedvialog-logtransformation.(†)Hazardofipilimumaboverhazardofplacebowithtwo-sided95%CIbasedon
unstratifiedCoxproportionalhazardsmodelwithtreatmentasthesinglecovariate.(‡)Unstratifiedtwo-sidedlog-ranktest.
6 ©2016byAmericanSocietyofClinicalOncology JOURNALOFCLINICALONCOLOGY
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
IpilimumabPlusChemotherapyVersusChemotherapyinFirst-LineED-SCLC
population (ORR, approximately 60%; median OS, approxi-
Table2. TumorResponse mately9.4months).3,11TherationaleforthisphaseIIItrialwas
No.(%) supported by preclinical studies showing synergistic effects of
ChemotherapyPlus ChemotherapyPlus
ipilimumabwithplatinumandetoposide21,22andresultsfrom
Ipilimumab Placebo the phase II trial of phased ipilimumab in combination with
BestOverallResponse (n=478) (n=476)
carboplatin and paclitaxel in ED-SCLC.17 It is unclear why
Bestoverallresponserate* 297(62) 296(62) ipilimumab did not confer additional benefit over etoposide
95%CI 58to67 58to67
Completeresponse 1(,1) 0 and platinum. One possible explanation is that without cor-
Partialresponse 296(62) 296(62) responding T-cell activation in the tumor microenvironment,
Stabledisease 125(26) 126(27) ipilimumab monotherapy, which stimulates peripheral T-cell
Progressivedisease 29(6) 42(9) activation, may not be effective in mounting a sufficiently
Unknown 27(6) 12(3)
Durationofresponse,months† strong antitumor response in ED-SCLC. In addition, con-
Median 4.01 3.45 comitant chemotherapy may increase immunosuppression,
95%CI 3.32to4.17 3.25to4.07 which may be associated with limited T-cell activation and
*Per modified WHO criteria, two-sided 95% CIs calculated using Clopper- proliferation.
Pearsonmethod. Results from previous efforts to identify prognostic and
†Computed using Kaplan-Meier method; medians and two-sided 95% CIs
calculatedvialog-logtransformation.Durationofresponsewasdefinedastime predictive biomarkers for anti-CTLA4 antibodies have been in-
betweendateofresponseofconfirmedcompleteresponseorconfirmedpartial conclusive.Inmelanoma,exploratorystudieshavesuggestedthat
response(whicheveroccurredfirst)anddateofprogressivediseaseordeath
(whicheveroccurredfirst). low baseline levels of circulating myeloid-derived suppressor
cells, low lactate dehydrogenase levels, low absolute monocyte
counts, high levels of circulating regulatory T cells, and high
relative lymphocyte counts may be associated with favorable
systemictherapywasreceivedbyasimilarpercentageofpatientsin outcomeswithipilimumab.28-30However,validationisrequiredin
both arms of the study. The safety profile of chemotherapy plus larger patient populations, and not all markers were consistent
ipilimumab was consistent with that in prior chemotherapy plus acrosstumortypes.31AninvitrostudyinSCLCdemonstratedthat
ipilimumabcombinationstudies,17,19,23andnonewsafetysignals thenumberandfrequencyofCD14+HLA–antigenDrelated/low
were identified. Immune-related toxicities were managed with myeloid-derived suppressor cells could be associated with poor
established safety guidelines, and a majority of grade 2 to 4 prognosis.32AretrospectivestudyofpatientswithSCLCreported
immune-related events resolved. that the ratio of C-reactive protein to albumin could be an in-
The performance of etoposide and platinum in this trial dependentpredictorofOS.33Bothstudiesprovideearlyevidence,
was consistent with that in previous studies in this patient but further research is required.
Table3. Treatment-RelatedAEsReportedin$5%ofPatientsTreatedWithChemotherapyPlusIpilimumaborChemotherapyPlusPlacebo
No.(%)
ChemotherapyPlusIpilimumab ChemotherapyPlusPlacebo
(n=478) (n=476)
AdverseEvent* AnyGrade Grade3to5† AnyGrade Grade3to5‡
TotalpatientswithAE§ 391(82) 231(48) 361(76) 214(45)
Diarrhea 121(25) 35(7) 46(10) 3(1)
Neutropenia 115(24) 69(14) 156(33) 113(24)
Anemia 113(24) 39(8) 137(29) 52(11)
Nausea 109(23) 7(1) 75(16) 3(1)
Rash 90(19) 8(2) 12(3) 0
Fatigue 62(13) 11(2) 53(11) 1(,1)
Decreasedappetite 58(12) 9(2) 39(8) 1(,1)
Pruritus 55(12) 3(1) 8(2) 0
Neutrophilcountdecreased 49(10) 32(7) 44(9) 29(6)
Vomiting 48(10) 5(1) 33(7) 3(1)
Thrombocytopenia 44(9) 18(4) 46(10) 21(4)
Leukopenia 27(6) 7(1) 52(11) 17(4)
Colitis 31(6) 20(4)§ 1(,1) 1(,1)
Alopecia 25(5) 0 35(7) 1(,1)
WBCcountdecreased 23(5) 6(1) 37(8) 13(3)
Hemoglobindecreased 25(5) 5(1) 14(3) 3(1)
Plateletcountdecreased 20(4) 8(2) 24(5) 4(1)
Abbreviation:AE,adverseevent.
*Includeseventswithonsetonorafterday1ofblindedstudytherapyandnolaterthan90daysafterlastdoseofstudytherapy.Somepatientshadmorethanoneevent.
†Grade5eventsofpneumonia(n=1),sepsis(n=1),colitis(n=1),andulcerativecolitis(n=1)werereported.
‡Grade5eventsofsepsis(n=1),multiorganfailure(n=1),andbonemarrowfailure(n=1)werereported.
§Onegrade5eventwasreported.
www.jco.org ©2016byAmericanSocietyofClinicalOncology 7
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
Recketal
Arecentreportshowedthatprogrammeddeathligand1(PD-L1) NCT02538666],STIMULI [Small CellLung CarcinomaTrial With
isexpressedintumor-infiltratingimmunecellsintheSCLCstroma, Nivolumab and IpiliMUmab in LImited Disease; clinical trial in-
althoughnotintumorcells,34indicatingthatpatientswithSCLC formation: NCT02046733], and a phase II trial of pembrolizumab
withstromalPD-L1expressionmaypotentiallyrespondtoinhibitors [clinicaltrialinformation:NCT02359019])orinsecond-linesettings
of the programmed death-1 (PD-1) immune checkpoint pathway. inSCLC(CheckMate331[clinicaltrialinformation:NCT02481830],
PD-1 inhibitors nivolumab and pembrolizumab and PD-L1 in- KEYNOTE-158 [clinical trial information: NCT02628067], and
hibitors durvalumab and atezolizumab have demonstrated antitu- a phase IIstudyof paclitaxel and pembrolizumab [clinical trial in-
moractivityandmanageablesafetyinvarioustumortypes.35-47PD-1 formation: NCT02551432]).
inhibitors, which target tumor-infiltrating lymphocytes, comple-
menttheantitumoractivityofCTLA-4inhibitorsbyactingthrough
AUTHORS’DISCLOSURES OF POTENTIALCONFLICTS
nonredundantpathways.20Thecombinationofnivolumaband
OF INTEREST
ipilimumab has demonstrated synergistic antitumor activity in
multipletumortypes,including melanomaandNSCLC.16,38,48-50
Disclosuresprovidedbytheauthorsareavailablewiththisarticleat
InpatientswithPD-L1–positiveED-SCLCwhodidnotrespond
www.jco.org.
to first-line therapy, pembrolizumab yielded a 29% ORR, with
durable responses (phase I KEYNOTE-028 study; clinical trial in-
formation:NCT02054806).16Nivolumabaloneandincombination AUTHOR CONTRIBUTIONS
withipilimumabyieldeddurableobjectiveresponses(ORRsof13%
and 31%, respectively), encouraging survival (median OS, 3.6 and Conceptionanddesign:MartinReck,Yi-longWu,ChristophZielinski,
7.8months,respectively),andmanageablesafetyprofilesinheavily KazuhikoNakagawa,AnnePieters,JustinFairchild,DavidSpigel
pretreatedpatientswithadvancedSCLC(phaseI/IICheckMate032 Provisionofstudymaterialsorpatients:MartinReck,Sang-WeKim,
study; clinical trial information: NCT01928394).15 Other immu- MichaelThomas,KathrynGold,LeoraHorn,JoachimAerts,PaulLorigan,
DavidSpigel
notherapeuticagents, including tumor vaccines(eg,polysialicacid,
Collectionandassemblyofdata:MartinReck,AlexanderLuft,Aleksandra
p53-expressingdendriticcells,andBec2),havehadlimitedsuccessin Szczesna,LiborHavel,Sang-WeKim,MariaCatherinePietanza,Yi-long
clinical trialsin SCLC.51 Wu,MichaelThomas,KathrynGold,LeoraHorn,JoachimAerts,Paul
Inconclusion,theadditionofipilimumabtoetoposideand Lorigan,TeresaKongSanchez,JustinFairchild,DavidSpigel
platinum did not improve OS compared with etoposide and Dataanalysisandinterpretation:MartinReck,WallaceAkerley,Maria
CatherinePietanza,Yi-longWu,ChristophZielinski,EnriquetaFelip,
platinum in chemotherapy-naive patients with ED-SCLC. To
LeoraHorn,KazuhikoNakagawa,PaulLorigan,AnnePieters,TeresaKong
date, PD-1 inhibitors, alone or in combination with CTLA-4
Sanchez,JustinFairchild,DavidSpigel
inhibitors, show the most promise in SCLC.15,16 Ongoing ap-
Manuscriptwriting:Allauthors
proaches include exploring these agents as maintenance after Finalapprovalofmanuscript:Allauthors
first-linechemotherapy(CheckMate451[clinicaltrialinformation:
Accountableforallaspectsofthework:Allauthors
a randomized clinical trial—The “Petites Cellules” CD4+andCD62LhighCD25+CD4+regulatoryTcells
REFERENCES Group.EurRespirJ5:286-290,1992 insmallcelllungcancerreflectsdiseasestage.Clin
8. LaraPNJr,NataleR,CrowleyJ,etal:PhaseIII CancerRes14:6770-6779,2008
1. HerbstRS,HeymachJV,LippmanSM:Lung trialofirinotecan/cisplatincomparedwithetoposide/ 15. AntoniaSJ,Lo´pez-MartinJA,BendellJ,etal:
cancer.NEnglJMed359:1367-1380,2008 cisplatin in extensive-stage small-cell lung cancer: Nivolumabaloneandnivolumabplusipilimumabin
2. vanMeerbeeckJP,FennellDA,DeRuysscher ClinicalandpharmacogenomicresultsfromSWOG recurrentsmall-celllungcancer(CheckMate032):A
DK: Small-cell lung cancer. Lancet 378:1741-1755, S0124.JClinOncol27:2530-2535,2009 multicentre,open-label,phase1/2trial.LancetOncol
2011 9. SchillerJH,AdakS,CellaD,etal:Topotecan 10.1016/S1470-2045(16)30098-5 [epub ahead of
3. ByersLA,RudinCM:Smallcelllungcancer: versusobservationaftercisplatinplusetoposidein printonJune3,2016]
Wheredowe gofrom here?Cancer121:664-672, extensive-stage small-cell lung cancer: E7593—A 16. Ott PA, Elez Fernandez ME, Hiret S, et al:
2015 phaseIIItrialoftheEasternCooperativeOncology Pembrolizumab for extensive-stage SCLC: Efficacy
4. Roth BJ, Johnson DH, Einhorn LH, et al: Group.JClinOncol19:2114-2122,2001 andrelationshipwithPD-L1expression.Presentedat
Randomizedstudyofcyclophosphamide,doxorubi- 10. Lally BE, Urbanic JJ, Blackstock AW, et al: the16thWorldConferenceonLungCancer,Denver,
cin, and vincristine versus etoposide and cisplatin Smallcelllungcancer:Havewemadeanyprogress CO,September6-9,2015(abstr3285)
versusalternationofthesetworegimensinexten- over the last 25 years? Oncologist 12:1096-1104, 17. ReckM,BondarenkoI,LuftA,etal:Ipilimu-
sive small-cell lung cancer: A phase III trial of the 2007 mabincombinationwithpaclitaxelandcarboplatinas
SoutheasternCancerStudyGroup.JClinOncol10: 11. OzeI,HottaK,KiuraK,etal:Twenty-seven first-linetherapyinextensive-disease-small-celllung
282-291,1992 yearsofphaseIIItrialsforpatientswithextensive cancer: Results from a randomized, double-blind,
5. National Comprehensive Cancer Network: diseasesmall-celllungcancer:Disappointingresults. multicenterphase2trial.AnnOncol24:75-83,2013
Clinicalpracticeguidelinesinoncology:Smallcelllung PLoSOne4:e7835,2009 18. Hodi FS, O’Day SJ, McDermott DF, et al:
cancer(version1).https://www.nccn.org/professionals/ 12. PeiferM,Ferna´ndez-CuestaL,SosML,etal: Improvedsurvivalwithipilimumab inpatientswith
physician_gls/pdf/sclc.pdf Integrative genome analyses identify key somatic metastaticmelanoma.NEnglJMed363:711-723,
6. Fru¨h M, De Ruysscher D, Popat S, et al: drivermutationsofsmall-celllungcancer.NatGenet 2010
Small-cell lung cancer (SCLC): ESMO clinical 44:1104-1110,2012 19. RobertC,ThomasL,BondarenkoI,etal:Ipi-
practice guidelines for diagnosis, treatment 13. DarnellRB:Onconeuralantigensandthepara- limumab plus dacarbazine for previously untreated
and follow-up. Ann Oncol 24:vi99-vi105, 2013 neoplasticneurologicdisorders:Attheintersectionof metastaticmelanoma.NEnglJMed364:2517-2526,
(suppl6) cancer,immunity,andthebrain.ProcNatlAcadSci 2011
7. LebeauB,ChastangC,AllardP,etal:Sixvs USA93:4529-4536,1996 20. PardollDM:Theblockadeofimmunecheck-
twelve cycles for complete responders to chemo- 14. Koyama K, Kagamu H, Miura S, et al: Re- pointsincancerimmunotherapy.NatRevCancer12:
therapyinsmallcelllungcancer:Definitiveresultsof ciprocalCD4+T-cellbalanceofeffectorCD62Llow 252-264,2012
8 ©2016byAmericanSocietyofClinicalOncology JOURNALOFCLINICALONCOLOGY
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
IpilimumabPlusChemotherapyVersusChemotherapyinFirst-LineED-SCLC
21. Spigel DR, Socinski MA: Rationale for che- 31. SantegoetsSJ,StamAG,LougheedSM,etal: 41. Motzer RJ, Escudier B, McDermott DF,
motherapy, immunotherapy, and checkpoint block- Myeloidderivedsuppressoranddendritic cellsub- et al: Nivolumab versus everolimus in advanced
adeinSCLC:beyondtraditionaltreatmentapproaches. setsarerelatedtoclinicaloutcomeinprostatecancer renal-cell carcinoma. N Engl J Med 373:1803-1813,
JThoracOncol8:587-598,2013 patientstreatedwithprostateGVAXandipilimumab. 2015
22. Jure-Kunkel M, Masters G, Girit E, et al: JImmunotherCancer2:31,2014 42. Garon EB, Rizvi NA, Hui R, et al: Pem-
Synergy between chemotherapeutic agents and 32. TianT,GuX,ZhangB,etal:Increasedcircu- brolizumabforthetreatmentofnon-small-celllung
CTLA-4blockadeinpreclinicaltumormodels.Cancer lating CD14(+)HLA-DR-/low myeloid-derived sup- cancer.NEnglJMed372:2018-2028,2015
ImmunolImmunother62:1533-1545,2013 pressorcellsareassociatedwithpoorprognosisin 43. RibasA,PuzanovI,Dummer R,etal:Pem-
23. LynchTJ,BondarenkoI,LuftA,etal:Ipilimumab patientswithsmall-celllungcancer.CancerBiomark brolizumabversusinvestigator-choicechemotherapy
incombinationwithpaclitaxelandcarboplatinasfirst- 15:425-432,2015 foripilimumab-refractorymelanoma(KEYNOTE-002):
linetreatmentinstageIIIB/IVnon–small-celllungcan- 33. ZhouT,ZhanJ,HongS,etal:RatioofC-reactive Arandomised,controlled,phase2trial.LancetOncol
cer: Results from a randomized, double-blind, multi- protein/albuminisaninflammatoryprognosticscore 16:908-918,2015
centerphaseIIstudy.JClinOncol30:2046-2054,2012 forpredictingoverallsurvivalofpatientswithsmall-cell 44. RobertC,SchachterJ,LongGV,etal:Pem-
24. Miller AB, Hoogstraten B, Staquet M, et al: lungcancer.SciRep5:10481,2015 brolizumab versus ipilimumab in advanced mela-
Reporting results of cancer treatment. Cancer 47: 34. Ilie M, Hofman V, Long E, et al: PD-L1 ex- noma.NEnglJMed372:2521-2532,2015
207-214,1981 pression in primary tumor and circulating tumor 45. FehrenbacherL,SpiraA,BallingerM,etal:
25. O’Day SJ, Maio M, Chiarion-Sileni V, et al: cells in patients with small cell lung carcinomas. Atezolizumab versus docetaxel for patients with
Efficacy and safety of ipilimumab monotherapy in PresentedattheAmericanAssociationofCancer previously treated non-small-cell lung cancer
patients with pretreated advanced melanoma: A Research, New Orleans, LA, April 16-20, 2016 (POPLAR): A multicentre, open-label, phase 2
multicentersingle-armphaseIIstudy.AnnOncol21: (abstr2220) randomised controlled trial. Lancet 387:1837-1846,
1712-1717,2010 35. GettingerSN,HornL,GandhiL,etal:Overall 2016
26. WolchokJD,NeynsB,LinetteG,etal:Ipili- survival and long-term safety of nivolumab (anti- 46. RosenbergJE,Hoffman-CensitsJ,PowlesT,
mumab monotherapy in patients with pretreated programmeddeath1 antibody,BMS-936558,ONO- etal:Atezolizumabinpatientswithlocallyadvanced
advanced melanoma: A randomised, double-blind, 4538) in patients with previously treated advanced andmetastaticurothelialcarcinomawhohavepro-
multicentre, phase 2, dose-ranging study. Lancet non–small-celllungcancer.JClinOncol33:2004-2012, gressed following treatment with platinum-based
Oncol11:155-164,2010 2015 chemotherapy: A single-arm, multicentre, phase 2
27. Weber J, Thompson JA, Hamid O, et al: A 36. BorghaeiH,Paz-AresL,HornL,etal:Nivo- trial.Lancet387:1909-1920,2016
randomized,double-blind,placebo-controlled,phase lumabversusdocetaxelinadvancednonsquamous 47. Antonia S, Goldberg SB, Balmanoukian A,
II study comparing the tolerability and efficacy of non-small cell lung cancer. N Engl J Med 373: etal:Safetyandantitumouractivityofdurvalumab
ipilimumabadministeredwithorwithoutprophylactic 1627-1639,2015 plustremelimumabinnon-smallcelllungcancer:A
budesonideinpatientswithunresectablestageIII 37. BrahmerJ,ReckampKL,BaasP,etal:Nivo- multicentre, phase 1b study. Lancet Oncol 17:
or IV melanoma. Clin Cancer Res 15:5591-5598, lumabversusdocetaxelinadvancedsquamous-cell 299-308,2016
2009 non-small-cell lung cancer. N Engl J Med 373: 48. Wolchok JD, Kluger H, Callahan MK, et al:
28. TarhiniAA,EdingtonH,ButterfieldLH,etal: 123-135,2015 Nivolumabplusipilimumabinadvancedmelanoma.
Immunemonitoringofthecirculationandthetumor 38. LarkinJ,Chiarion-SileniV,GonzalezR,etal: NEnglJMed369:122-133,2013
microenvironment in patients with regionally ad- Combined nivolumab and ipilimumab or mono- 49. Postow MA, Chesney J, Pavlick AC, et al:
vancedmelanomareceivingneoadjuvantipilimumab. therapyinuntreatedmelanoma.NEnglJMed373: Nivolumab and ipilimumab versus ipilimumab in
PLoSOne9:e87705,2014 23-34,2015 untreatedmelanoma.NEnglJMed372:2006-2017,
29. MeyerC,CagnonL,Costa-NunesCM,etal: 39. Weber JS, D’Angelo SP, Minor D, et al: 2015
Frequencies of circulating MDSC correlate with Nivolumab versus chemotherapy in patients with 50. Rizvi NA, Gettinger SN, Goldman JW,
clinicaloutcomeofmelanomapatientstreatedwith advanced melanoma who progressed after anti- etal:Safetyandefficacyoffirst-linenivolumab
ipilimumab.CancerImmunolImmunother63:247-257, CTLA-4treatment(CheckMate037):Arandomised, (NIVO; anti-programmed death-1 [PD-1]) and
2014 controlled,open-label,phase3trial.LancetOncol16: ipilimumab in non-small cell lung cancer
30. Martens A, Wistuba-Hamprecht K, Foppen 375-384,2015 (NSCLC).JThoracicOncol10:S176,2015(suppl
MG,etal:Baselineperipheralbloodbiomarkersas- 40. Motzer RJ, Rini BI, McDermott DF, et al: 2;oral02.05)
sociated with clinical outcome of advanced mela- Nivolumabformetastaticrenalcellcarcinoma:Re- 51. ReckM,HeigenerD,ReinmuthN:Immuno-
nomapatientstreatedwithipilimumab.ClinCancer sultsofarandomizedphaseIItrial.JClinOncol33: therapy for small-cell lung cancer: Emerging evi-
Res22:2908-2918,2016 1430-1437,2015 dence.FutureOncol12:931-943,2016
Affiliations
Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf; Michael Thomas, Translational Lung
ResearchCenterHeidelberg,ThoraxklinikimUniversita¨tsklinikumHeidelberg,Heidelberg,Germany;AlexanderLuft,LeningradRegional
ClinicalHospital,Leningrad,Russia;AleksandraSzczesna,MazowieckieCentrumLeczeniaChorobPluciGruzlicywOtwocku,Otwocku,
Poland;LiborHavel,HospitalNaBulovce,Prague,CzechRepublic;Sang-WeKim,AsanMedicalCenterandUniversityofUlsanCollegeof
Medicine,Seoul,Korea;WallaceAkerley,HuntsmanCancerInstitute,UniversityofUtah,SaltLakeCity,UT;MariaCatherinePietanza,
MemorialSloanKetteringCancerCenter,NewYork,NY;KathrynGold,UniversityofTexasMDAndersonCancerCenter,Houston,TX;
LeoraHorn,Vanderbilt-IngramCancerCenter;DavidSpigel,SarahCannonResearchInstituteandTennesseeOncology,Nashville,TN;
Anne Pieters, Teresa Kong Sanchez, and Justin Fairchild, Bristol-Myers Squibb, Princeton, NJ; Yi-long Wu, Guangdong Lung Cancer
Institute, Guangdong General Hospital, Guangdong, People’s Republic of China; Christoph Zielinski, Medical University of Vienna,
Vienna, Austria; Enriqueta Felip, Vall d’Hebron University Hospital, Barcelona, Spain; Joachim Aerts, Erasmus MC Cancer Institute,
Rotterdam, the Netherlands; Kazuhiko Nakagawa, Kinki University Hospital, Osaka, Japan; and Paul Lorigan, the Christie NHS
Foundation Trust, Manchester, United Kingdom.
n n n
www.jco.org ©2016byAmericanSocietyofClinicalOncology 9
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
Recketal
AUTHORS’DISCLOSURESOFPOTENTIALCONFLICTSOFINTEREST
PhaseIIIRandomizedTrialofIpilimumabPlusEtoposideandPlatinumVersusPlaceboPlusEtoposideandPlatinuminExtensive-StageSmall-Cell
LungCancer
Thefollowingrepresentsdisclosureinformationprovidedbyauthorsofthismanuscript.Allrelationshipsareconsideredcompensated.Relationshipsare
self-heldunlessnoted.I=ImmediateFamilyMember,Inst=MyInstitution.Relationshipsmaynotrelatetothesubjectmatterofthismanuscript.Formore
informationaboutASCO’sconflictofinterestpolicy,pleaserefertowww.asco.org/rwcorjco.ascopubs.org/site/ifc.
MartinReck KathrynGold
ConsultingorAdvisoryRole:Hoffmann-LaRoche,EliLilly, Honoraria:Genentech
Bristol-MyersSquibb,MerckSharp&Dohme,AstraZeneca,Pfizer, ResearchFunding:Pharmacyclics,Bristol-MyersSquibb,AstraZeneca,
BoehringerIngelheim ARIADPharmaceuticals,Genentech,AstellasPharma,Boehringer
Speakers’Bureau:Hoffmann-LaRoche,EliLilly,Bristol-MyersSquibb, Ingelheim
MerckSharp&Dohme,AstraZeneca,Pfizer,Celgene,Boehringer Travel,Accommodations,Expenses:AstraZeneca
Ingelheim
LeoraHorn
AlexanderLuft ConsultingorAdvisoryRole:Bristol-MyersSquibb,Merck,Bayer
Norelationshiptodisclose HealthCarePharmaceuticals,Xcovery,Genentech,BoehringerIngelheim,
EliLilly,AbbVie
AleksandraSzczesna
ResearchFunding:AstraZeneca
Norelationshiptodisclose
Travel,Accommodations,Expenses:Bristol-MyersSquibb
LiborHavel OtherRelationships:Biodesix
ConsultingorAdvisoryRole:Bristol-MyersSquibb,MerckSharp&
JoachimAerts
Dohme,Amgen,Roche,EliLilly
StockorOtherOwnership:Amphera
Sang-WeKim ConsultingorAdvisoryRole:Bristol-MyersSquibb,MerckSharp&
Norelationshiptodisclose Dohme,BoehringerIngelheim,Genentech,EliLilly,Amphera,Roche
Speakers’Bureau:AstraZeneca
WallaceAkerley ResearchFunding:Genentech(Inst)
Norelationshiptodisclose Patents,Royalties,OtherIntellectualProperty:Tumor-celllysate(Inst),
Amphera
MariaCatherinePietanza
Travel,Accommodations,Expenses:Verastem,MerckSharp&Dohme
Employment:Merck
Honoraria:Celgene,AbbVie,ClovisOncology,Novartis,Bristol-Myers KazuhikoNakagawa
Squibb Honoraria:Bristol-MyersSquibb
ConsultingorAdvisoryRole:Celgene,AbbVie,ClovisOncology, ResearchFunding:Bristol-MyersSquibb(Inst),AstraZeneca(Inst),
Novartis,Bristol-MyersSquibb OnoPharmaceutical(Inst),MerckSharp&Dohme(Inst)
Speakers’Bureau:PhysicianEducationResource
ResearchFunding:StemCentRx(Inst),Novartis(Inst),Bristol-Myers PaulLorigan
Squibb(Inst) Honoraria:Amgen,Bristol-MyersSquibb,ChugaiPharmaceutical,
GlaxoSmithKline,Merck,Novartis,Roche,Agenus,Lytix
Yi-longWu ConsultingorAdvisoryRole:Amgen,Bristol-MyersSquibb,Chugai
Honoraria:AstraZeneca,EliLilly,Roche,PierreFabre,Pfizer,Sanofi
Pharmaceutical,GlaxoSmithKline,Merck,Novartis,Roche,Lytix,Agenus
ConsultingorAdvisoryRole:AstraZeneca,Roche,Merck,Boehringer Speakers’Bureau:Bristol-MyersSquibb,ChugaiPharmaceutical,
Ingelheim GlaxoSmithKline,Merck,Roche
ResearchFunding:BoehringerIngelheim(Inst),Roche(Inst) Travel,Accommodations,Expenses:Agenus,Amgen,Bristol-Myers
Squibb,ChugaiPharmaceutical,GlaxoSmithKline,Merck,Novartis,
ChristophZielinski
Roche,Lytix
Honoraria:Bristol-MyersSquibb
ConsultingorAdvisoryRole:Bristol-MyersSquibb AnnePieters
Travel,Accommodations,Expenses:Bristol-MyersSquibb Employment:Bristol-MyersSquibb
StockorOtherOwnership:Bristol-MyersSquibb
MichaelThomas
Honoraria:Roche,Bristol-MyersSquibb,EliLilly,AstraZeneca,Novartis, TeresaKongSanchez
Pfizer,BoehringerIngelheim,Celegene,MerckSharp&Dohme
Employment:Bristol-MyersSquibb
ConsultingorAdvisoryRole:Novartis,EliLilly,Pfizer,Bristol-Myers
StockorOtherOwnership:Bristol-MyersSquibb
Squibb,Roche,AstraZeneca,BoehringerIngelheim,MerckSharp&
Dohme,Celgene JustinFairchild
ResearchFunding:Roche(Inst),EliLilly(Inst) Employment:Bristol-MyersSquibb
Travel,Accommodations,Expenses:Roche,Pfizer,Boehringer StockorOtherOwnership:Bristol-MyersSquibb
Ingelheim,Novartis,EliLilly,Bristol-MyersSquibb,MerckSharp&
DavidSpigel
Dohme
ConsultingorAdvisoryRole:Bristol-MyersSquibb
EnriquetaFelip ResearchFunding:Bristol-MyersSquibb
ConsultingorAdvisoryRole:EliLilly,Pfizer,Roche,Boehringer Travel,Accommodations,Expenses:Genentech,Novartis,Celgene,
Ingelheim,Bristol-MyersSquibb,MerckSharp&Dohme,Novartis,
Bristol-MyersSquibb,EliLilly,AstraZeneca,Pfizer,ClovisOncology,
Celgene Biodesix,BoehringerIngelheim
Speakers’Bureau:Bristol-MyersSquibb,Novartis,Roche
©2016byAmericanSocietyofClinicalOncology JOURNALOFCLINICALONCOLOGY
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
IpilimumabPlusChemotherapyVersusChemotherapyinFirst-LineED-SCLC
Acknowledgment
Wethankthepatientsandtheirfamiliesaswellastheparticipatingstudyteamsformakingthisstudypossible.WealsothankKarenTimko
forherroleasprotocolmanager.ProfessionalmedicalwritingandeditorialassistancewereprovidedbyVasupradhaVethantham,PhD,and
Anne Cooper, MA.
www.jco.org ©2016byAmericanSocietyofClinicalOncology
Information downloaded from jco.ascopubs.org and provided by at Weill Cornell Medical Library on July 25, 2016 from
Copyright © 2016 American S2o0c7ie.1ty6 2o.f2 C4l0in.1ic4a7l Oncology. All rights reserved.
